Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18427349 | 1.00 | STING1 (0.46) | STING1MEN1MAPTKMT2AF10 | |
| SCHEMBL18427309 | 1.00 | STING1 (0.46) | STING1MEN1MAPTKMT2AF10 | |
| SCHEMBL3921970 | 0.91 | STING1 (0.46) | STING1MEN1MAPTKMT2AF10 | |
| SCHEMBL5524426 | 0.91 | STING1 (0.44) | STING1MEN1MAPTKMT2AF10 | |
| SCHEMBL14691305 | 0.90 | STING1 (0.42) | STING1MEN1MAPTKMT2AF10 | |
| SCHEMBL31160647 | 0.89 | STING1 (0.44) | STING1MEN1MAPTKMT2AF10 | |
| SCHEMBL31161069 | 0.89 | STING1 (0.44) | STING1MEN1MAPTKMT2AF10 | |
| SCHEMBL31160649 | 0.89 | STING1 (0.44) | STING1MEN1MAPTKMT2AF10 | |
| SCHEMBL17358246 | 0.88 | STING1 (0.42) | STING1MEN1MAPTKMT2AF10 | |
| SCHEMBL17358236 | 0.88 | STING1 (0.42) | STING1MEN1MAPTKMT2AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317437-B1 | SYNTHESIS OF 4-ALPHA-ARYLEPICATECHINS | MARS INC (US) | 2007-10-03 | — | — | EP | claimed |
| US-20050020512-A1 | Synthesis of oligomeric epicatechin and catechin-derived procyanidins | MARS, INCORPORATED | 2005-01-27 | — | — | US | claimed |
| US-6476241-B1 | Synthesis of 4α-arylepicatechins | MARS INCORPORATED | 2002-11-05 | — | — | US | claimed |
| EP-1317437-B1 | SYNTHESIS OF 4-ALPHA-ARYLEPICATECHINS | MARS INC (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070197804-A1 | Synthesis of 4alpha-arylepicatechins | MARS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-7126014-B2 | Synthesis of epecatechin-4α, 8-epicatechin and -catechin dimers and derivatives thereof | MARS, INC. | 2006-10-24 | — | — | US | disclosed |
| US-7015338-B1 | Synthetic methods for preparing procyanidin oligomers | MARS INCORPORATED (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050014958-A1 | Synthesis of 4alpha-arylepicatechins | MARS, INCORPORATED | 2005-01-20 | — | — | US | disclosed |
| US-6720432-B2 | OXIDIZING HYDROXYL-PROTECTED BENZYLEPITCATECHIN, ADDING NUCLEOPHILIC ARYL-ORGANOMETALLIC REAGENT, AND DEOXYGENATING FORMING COMPOUNDS SUCH AS 3,5,7,3',4'-PENTA-O-BENZYL-4-HYDROXYEPICATECHIN; PROCYANIDINS | MARS INCORPORATED | 2004-04-13 | — | — | US | disclosed |
| EP-1317437-A2 | SYNTHESIS OF 4-ALPHA-ARYLEPICATECHINS | Mars Incorporated (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030100775-A1 | Synthesis of 4alpha-arylepicatechins | MARS INCORPORATED | 2003-05-29 | — | — | US | disclosed |
| US-6476241-B1 | Synthesis of 4α-arylepicatechins | MARS INCORPORATED | 2002-11-05 | — | — | US | disclosed |
| WO-2002020506-A2 | SYNTHESIS OF 4α-ARYLEPICATECHINS | MARS, INCORPORATED (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100775-A1 | Synthesis of 4alpha-arylepicatechins | FABP4, TEAD4, FABP7 | STING1 4810/4885MEN1 4010/4885MAPT 2148/4885 |
| US-20050014958-A1 | Synthesis of 4alpha-arylepicatechins | FABP7, FABP4, TEAD4 | STING1 4810/4885MEN1 3950/4885MAPT 1948/4885 |
| US-20070197804-A1 | Synthesis of 4alpha-arylepicatechins | FABP7, FABP4, TEAD4 | STING1 4810/4885MEN1 3950/4885MAPT 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.